Davenport & CO LLC Argenx Se Transaction History

Davenport & CO LLC

$16.8 Billion
Q3 2024

A detailed history of Davenport & CO LLC transactions in Argenx Se stock. As of the latest transaction made, Davenport & CO LLC holds 1,528 shares of ARGX stock, worth $903,720. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,528

Previous 1,447 5.6%

Holding current value

$903,720

Previous $622,000 33.12%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	BUY	$434.22 - $551.9 $35,171 - $44,703	81 Added 5.6%	1,528 $828,000
Q2 2024 Aug 06, 2024	BUY	$356.01 - $451.55 $54,113 - $68,635	152 Added 11.74%	1,447 $622,000
Q1 2024 May 03, 2024	SELL	$356.95 - $413.29 $92,093 - $106,628	-258 Reduced 16.61%	1,295 $509,000
Q4 2023 Jan 23, 2024	BUY	$338.91 - $506.01 $49,480 - $73,877	146 Added 10.38%	1,553 $590,000
Q3 2023 Oct 17, 2023	BUY	$369.35 - $548.43 $54,663 - $81,167	148 Added 11.76%	1,407 $691,000
Q2 2023 Jul 20, 2023	SELL	$360.14 - $422.58 $38,174 - $44,793	-106 Reduced 7.77%	1,259 $490,000
Q1 2023 Apr 27, 2023	BUY	$334.23 - $403.65 $79,880 - $96,472	239 Added 21.23%	1,365 $508,000
Q4 2022 Jan 20, 2023	SELL	$342.17 - $402.31 $35,927 - $42,242	-105 Reduced 8.53%	1,126 $0
Q3 2022 Oct 11, 2022	SELL	$343.2 - $395.75 $103,646 - $119,516	-302 Reduced 19.7%	1,231 $435,000
Q2 2022 Jul 18, 2022	BUY	$269.58 - $378.88 $14,018 - $19,701	52 Added 3.51%	1,533 $581,000
Q1 2022 May 02, 2022	BUY	$254.45 - $351.06 $25,953 - $35,808	102 Added 7.4%	1,481 $467,000
Q4 2021 Feb 10, 2022	BUY	$272.01 - $353.03 $110,164 - $142,977	405 Added 41.58%	1,379 $483,000
Q3 2021 Oct 14, 2021	BUY	$295.0 - $350.58 $24,485 - $29,098	83 Added 9.32%	974 $294,000
Q2 2021 Jul 28, 2021	BUY	$257.11 - $319.92 $229,085 - $285,048	891 New	891 $268,000

Others Institutions Holding ARGX

# of Institutions

384

Shares Held

31.6M

Call Options Held

338K

Put Options Held

449K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $32.7B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.

Account